Gastric Cancer EFS Improves With Perioperative Serplulimab
Episode Summary
ASTRUM-006 found serplulimab plus perioperative SOX improved event-free survival in PD-L1-selected resectable gastric or gastroesophageal junction cancer, supporting biomarker-guided investigation.